Synaptogenix, Inc. (SNPX)

NASDAQ: SNPX · Real-Time Price · USD

4.000

+0.420 (11.73%)

At close: Jun 24, 2025, 4:00 PM

3.730

-0.270 (-6.75%)

Pre-market: Jun 25, 2025, 7:19 AM EDT

Synaptogenix Employees

Synaptogenix had 4 employees as of December 31, 2024. The number of employees decreased by 1 or -20.00% compared to the previous year.

Employees

4

Change (1Y)

-1

Growth (1Y)

-20.00%

Revenue / Employee

n/a

Profits / Employee

-$3,241,366

Market Cap

5.56M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	4	-1	-20.00%
Dec 31, 2023	5	0	-
Dec 31, 2022	5	1	25.00%
Dec 31, 2021	4	0	-
Dec 31, 2020	4	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

SNPX News

22 hours ago - Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - PRNewsWire
15 days ago - Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token - PRNewsWire
6 months ago - Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - PRNewsWire
10 months ago - Synaptogenix Announces $5.0 Million Financing - PRNewsWire
1 year ago - Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury - PRNewsWire
1 year ago - Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis - PRNewsWire
1 year ago - Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery - PRNewsWire
1 year ago - Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing - PRNewsWire